Immune checkpoints as therapeutic targets in autoimmunity
Antibodies that block the immune checkpoint receptors PD1 and CTLA4 have revolutionized the treatment of melanoma and several other cancers, but in the process, a new class of drug side effect has emerged-immune related adverse events. The observation that therapeutic blockade of these inhibitory re...
Κύριοι συγγραφείς: | Paluch, C, Santos, A, Anzilotti, C, Cornall, R, Davis, S |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Frontiers Media
2018
|
Παρόμοια τεκμήρια
-
Immune Checkpoints as Therapeutic Targets in Autoimmunity
ανά: Christopher Paluch, κ.ά.
Έκδοση: (2018-10-01) -
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
ανά: Yujia Zhai, κ.ά.
Έκδοση: (2021-04-01) -
Combination CD200R/PD-1 blockade in a humanised mouse model
ανά: Fellermeyer, M, κ.ά.
Έκδοση: (2023) -
Manipulating immune checkpoint signalling pathways with antibodies
ανά: Paluch, C
Έκδοση: (2019) -
Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
ανά: Lauren S. Fane, κ.ά.
Έκδοση: (2022-09-01)